Bio-Techne (NASDAQ:TECH) Upgraded to “Strong-Buy” at Evercore

Posted by Brenda Bartman on Jun 26th, 2026

Bio-Techne (NASDAQ:TECH – Get Free Report) was upgraded by analysts at Evercore from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other brokerages also recently weighed in on TECH. Zacks Research downgraded shares of Bio-Techne from a “hold” rating to a “strong sell” rating in a report on Monday, June 8th. William Blair downgraded Bio-Techne from an “outperform” rating to a “market perform” rating in a research report on Thursday. Royal Bank Of Canada set a $62.00 price objective on Bio-Techne and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Robert W. Baird set a $49.00 target price on Bio-Techne in a research note on Thursday, May 7th. Finally, Leerink Partners set a $73.00 price target on Bio-Techne in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.79.

Read Our Latest Stock Analysis on Bio-Techne

Bio-Techne Stock Performance

Shares of TECH stock opened at $70.70 on Thursday. The firm has a market capitalization of $11.07 billion, a PE ratio of 102.47, a P/E/G ratio of 5.67 and a beta of 1.37. The company has a 50 day moving average price of $52.70 and a 200-day moving average price of $56.99. Bio-Techne has a 52 week low of $43.19 and a 52 week high of $72.16. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The company had revenue of $311.42 million during the quarter, compared to the consensus estimate of $316.11 million. During the same period last year, the firm posted $0.56 EPS. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, equities research analysts expect that Bio-Techne will post 1.66 earnings per share for the current year.

Institutional Investors Weigh In On Bio-Techne

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new position in shares of Bio-Techne during the 4th quarter valued at approximately $29,000. eCIO Inc. bought a new stake in Bio-Techne in the fourth quarter worth $30,000. Measured Wealth Private Client Group LLC purchased a new position in Bio-Techne during the third quarter worth $32,000. iSAM Funds UK Ltd purchased a new position in Bio-Techne during the third quarter worth $33,000. Finally, EverSource Wealth Advisors LLC increased its position in Bio-Techne by 506.3% during the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 562 shares during the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Techne News Roundup

Here are the key news stories impacting Bio-Techne this week:

Positive Sentiment: Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, giving shareholders a clear exit value and likely driving the stock toward the deal price. Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne
Positive Sentiment: The offer represents a sizable premium to Bio-Techne’s recent share price, which typically boosts takeover-target stocks as investors price in deal completion. Germany’s Merck to buy Bio-Techne for $73 per share
Neutral Sentiment: Multiple law firms announced shareholder investigations into whether Bio-Techne’s board secured a fair price, which could create legal noise but does not change the announced deal terms. Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Neutral Sentiment: Reported short-interest data showed no meaningful short position, so the move appears driven more by the takeover announcement than by short covering. Bio-Techne Surges on $73-Per-Share Cash Takeover Agreement

About Bio-Techne

(Get Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.